Correspondence

Isoniazid-induced liver disorder in the treatment of tuberculosis

Dear Editor,

Liver damage occurs in 18–20% of patients taking isoniazid; however, in most cases, a slight increase in serum glutamic oxaloacetate transaminase (SGOT) occurs when the medication is continued.1 Notwithstanding, in around 1% of patients, isoniazid causes hepatitis.2–4 There are currently no methods for determining whether a patient with a marginally increased SGOT will develop hepatitis upon continuing isoniazid.5 Clinical highlights are widely variable, ranging from gastrointestinal indications, a virus-like disease, or tricky jaundice to extreme touchiness such as fever, rash, and eosinophilia.6

The general conclusions were that liver sickness can occur in patients on isoniazid preventive treatment. Age is a prevalent factor that appears to increase the risk of liver damage among subjects accepting isoniazid.7 This dynamic liver harm occurs infrequently in patients <20 years old, up to 0.3% in patients aged 20–34 years, up to 1.2% in patients aged 35–49 years, and up to 2.3% in patients aged ≥50 years.8 Daily liquor consumption may likewise increase the risk. The recurrence may differ among places and times and contingent on unknown factors. The liver sickness that develops is not an after-effect of a specific assembling procedure or contaminant.9 The improvement of the liver malady is not surprising in any individual patient. The morphological pathology of isoniazid liver infection, as directly comprehended, does not allow its prepared separation from viral hepatitis.10 Routine checking by lab tests such as SGOT or serum glutamic pyruvate transaminase (SGPT) is not valuable for foreseeing hepatic maladies in patients taking isoniazid. Here we report on isoniazid-induced liver disorder in the treatment of tuberculosis.

Case 1 is a 40-year-old man who was admitted to the casualty medical ward in a tertiary care hospital complaining of fever, abdominal pain, persisting vomiting, breathlessness, and decreased sleep and appetite. He was diagnosed with sputum-positive pulmonary tuberculosis 2 months prior with positive radiological findings on a chest X-ray and started on category one anti-tubercular therapy (isoniazid 300 mg/day, rifampicin 600 mg/day, pyrazinamide 1.5 gm/day, ethambutol 800 mg/day, and pyridoxine 20 mg/day). The patient's medical record showed indinavir use and subsequent treatment with a tenofovir + lamivudine + nevirapine (TLN) regimen. There was no past personal or family history of liver disorder. The patient weighed 65.0 kg; his blood pressure and pulse rate at admission were 100/70 mmHg and 84 beats/min, respectively. The clinical examination revealed that all body systems were within normal limits except for liver function as evidenced by elevated bilirubin and liver enzymes. Within a few days after starting category one anti-tubercular therapy, signs of liver dysfunction were observed, the patient was treated symptomatically by the withdrawal of the anti-tubercular therapy and cured. The anti-tubercular therapy was restarted and he developed the same signs of liver dysfunction.

The patient’s signs of liver dysfunction were treated by withdrawal of the anti-tubercular therapy and symptomatic treatment with paracetamol, ondansetron, dicyclomine, and pantoprazole. The patient’s condition improved over the next 3 days; he was then discharged with modified anti-tubercular therapy without isoniazid. On review, his condition improved without any signs of liver dysfunction. The Naranjo Reverse Drug Reaction Probability Scale and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were applied to determine the cause of the suspected adverse drug reaction (ADR). The causality assessment with both scales revealed that the ADR being due to...
isoniazid in this case was “probable” (Naranjo overall score, 6); on the modified Hartwig and Siegel scale, it was categorized as a moderate 4(b) reaction.

Case 2 is a 60-year-old man who was admitted to the casualty medical ward in a tertiary care hospital with complaints of fever, abdominal discomfort, and generalized weakness. He was diagnosed with sputum-positive pulmonary tuberculosis with positive radiological findings on chest X-ray and started on category one anti-tubercular therapy (isoniazid 300 mg/day, rifampicin 600 mg/day, pyrazinamide 1.5 g/day, ethambutol 800 mg/day, and pyridoxine 20 mg/day). His medical record revealed a history of indinavir use and subsequent TLN regimen treatment. There was no past personal or family history of liver disorders. The patient weighed 75 kg and had an admission blood pressure and pulse rate of 120/90 mmHg and 86 beats/min, respectively. The clinical examination revealed that all body systems were within normal limits except for liver function, i.e., elevated bilirubin and liver enzyme levels.

The patient was diagnosed with positive pulmonary tuberculosis and started on category one anti-tubercular therapy. Within a few days, the patient had developed signs of liver dysfunction, which were treated by the withdrawal of anti-tubercular therapy and symptomatic treatment with ursodeoxycholic acid, pantoprazole, and ondansetron. The patient's condition improved over the next 3 days. He was then discharged with modified anti-tubercular therapy without isoniazid. On review, her condition improved without any signs of liver dysfunction. The causality assessment on both scales revealed that the ADR being due to isoniazid was “probable” (Naranjo overall score, 6); on the modified Hartwig and Siegel scale, it was categorized as a moderate 4(b) reaction.

Isoniazid is metabolized via an acetylation process by N-acetyltransferase (NAT-2) in the liver, where it is converted to acetyl isoniazid. The N-acetyl isoniazid undergoes hydrolysis to form acetyl hydrazine (AcHz). The polymorphisms of NAT-2 cause people to be either “quick” or “moderate” acetylate metabolizers. Slow acetylate metabolizers shunt some isoniazid to an optional metabolic pathway of oxidation via cytochrome P450, delivering hydrazine (Hz). This suggests that both AcHz and Hz, produced separately by the quick and moderate acetylate metabolizers, participate in responses that create oxidative pressure (e.g., free radicals). Hz may instigate cytochrome P450 (specifically CYP2E1), expanding the generation of an extra-harmful metabolite. Subsequently, hepatotoxicity may occur in both fast and moderate acetylate metabolizers, however for somewhat extraordinary reasons. Isoniazid acetylation forms ac-isoniazid via the N-acetyltransferase (NAT) enzyme, while hydrolysis delivers isonicotinic acid and Hz via amidase. Acisoniazid can likewise be hydrolyzed to form isonicotinic acid and AcHz. Moreover, Hz can be acetylated to AcHz and diacetyl Hz. Hz and AcHz are believed to be additionally oxidized to responsive metabolites and engaged with isoniazid hepatotoxicity, which was proposed to be intervened by microsomal P450, particularly CYP2E56.5

Once a drug-induced liver disorder develops, all conceivably hepatotoxic medications must be discontinued until the clinical and biochemical determination of the hepatotoxicity causation is made. In the meantime, no fewer than three non-hepatotoxic medications (e.g., ethambutol, streptomycin, and quinolones;
or levofloxacin, ofloxacin, or ciprofloxacin) can be utilized after suitable assessment of the patient's renal capacity and visual acuity. After the thorough determination of transaminases, most anti-tubercular medications can be carefully restarted. The British Thoracic Society suggested that primary anti-tubercular medications can be reintroduced sequentially in the order of isoniazid, rifampicin, and pyrazinamide with regular observation of the patient's biological condition and liver capacity. Isoniazid should be started at a dosage of 50 mg/day and gradually increased to 300 mg/day, more than a few days in the event that it is all around endured and preceded thereafter. A few days later, rifampicin can be started at a dosage of 75 mg/day and gradually increased to 300 mg/day. Thereafter, it can be increased to 450 mg (<50 kg) or 600 mg (>50 kg) according to the patient's weight. On the off chance that this medication is not well-tolerated, it is discontinued. And finally, pyrazinamide can be started at 250 mg/day, gradually increased to 1000 mg/day, and then increased to 1500 mg (<50 kg) or 2000 mg (>50 kg) according to the patient's body weight. On the off chance that these medications are not well-tolerated, they can be discontinued.

Tuberculosis is more pervasive in developing nations like India. Subsequently, physicians must know about the medication danger profiles of anti-tubercular drugs like isoniazid. The mental complexities can enormously affect the patients' personal satisfaction and a physician's state of mind about using isoniazid; thus, effective control of these inconveniences is critical. These case reports explain the features of isoniazid-induced liver disorders.

**Conflict of interest**

Authors do not have any conflict of interest.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cdtm.2018.11.003.

**References**

1. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. *J Clin Exp Hepatol*. 2013;3:37–49.
2. Pandit A, Sachdeva T, Bafna P. Drug-induced hepatotoxicity: a review. *J Appl Pharm Sci*. 2012;2:233–243.
3. Gangavaram JR, Vara PR, Mangura S, Cuddapa R, Sadhu NK, Rupesh SK. Evaluation of hepatoprotective potential of ethanolic extract of Ixora pavetta against isoniazid and rifampicin induced hepatotoxicity in rats. *Drug Invention Today*. 2013;5:201–206.
4. Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. *BMJ Infect Dis*. 2017;17:231.
5. Pengcheng W, Komal P, Xiao-bo Z, Xiaochao M. Isoniazid metabolism and hepatotoxicity. *Act Pharm Sin B*. 2016;5:384–392.
6. Attri S, Rana SV, Vaiphei K, et al. Isoniazid- and rifampicin-induced oxidative hepatic injury – protection by N-acetylcysteine. *Hum Exp Toxicol*. 2000;19:517–522.
7. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. *Chest*. 2005;128:116–123.
8. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. *In Vivo*. 2011;25:803–812.
9. Verma AK, Yadav A, Dewangan J, et al. Isoniazid prevents Nrf 2 translocation by inhibiting ERK1phosphorylation and induces oxidative stress and apoptosis. *Redox Biol*. 2015;6:80–92.
10. Srinivasan Sivannan, Atukuri Vishnuvardhan, Kirthikeyan Elumalai, Sivaneswari Srinivasan, Kalpana Eluri, Manogaran Elumalai, Ramasamy Muthu.

**Corresponding author.**

E-mail address: karthikeyanelumalai@hotmail.com (K. Elumalai)

21 September 2018